Health ❯ Healthcare ❯ Chronic Diseases

Diabetes

Type 2 Diabetes Obesity Management Strategies Type 1 Diabetes Diabetes Management Heart Disease Insulin Therapy Treatment Options GLP-1 Receptor Agonists Semaglutide Weight Management GLP-1 Agonists Hypertension Type 2 Diabetes Treatments Type 2 Diabetes Management Risk Factors Management and Treatment Monitoring Systems Diabetes Medications GLP-1 Drugs Type-2 Diabetes Management Kidney Disease GLP-1 Medications Weight Loss Medications Medications Prediabetes Brain Health Type 2 Diabetes Treatment Women's Health Tzield Type 2 Diabetes in Adolescents Nutrition Diabetes Mellitus Type 1 Weight Loss Treatments Chronic Kidney Disease Diabetes Type I Blood Sugar Control Remote Monitoring Treatment Innovations Obesity-related Cancer Obesity-related Complications Interconnectedness of Conditions Patient Support Diabetes Treatments Statistics GLP-1 Efficacy Diabetes Care Models Neck Circumference Cancer Diabetes Type 2 Type 1 Diabetes Management Glucose Control Gene Therapy Applications Monitoring Devices Risk Factors for Alzheimer's Cardiovascular Complications Dietary Guidance Older Adults Weight Loss Drugs Diabetic Retinopathy Awareness Programs Complications of Diabetes Myths and Misconceptions World Diabetes Day Oral Health Liver Fibrosis Cardiovascular Risk Prevention and Management Cardiovascular Health Health Assessments Blood Sugar Monitoring Prevalence in Older Adults Infection Management Antidiabetic Medications Patient Care Alzheimer's Disease GLP-1 Therapy Heart Conditions Impact of Type 2 Diabetes Health Risks of Diabetes Type 2 Diabetes Risk Factors High-Risk Diabetes Diabetic Foot Complications Impact on Eye Health Impact on Population Lifestyle Diseases Insulin Delivery Systems Type-2 Diabetes Type 2 Diabetes Mellitus Remission Strategies Complications Type II Diabetes Type 1 Diabetes Mellitus Type 2 Diabetes Trends Treatment Diabetic Foot Ulcers Diabetic Ketoacidosis Insulin Resistance Mortality Rates Metabolic Syndrome

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Officials say Yellow Card reports do not prove drugs caused harm.

Oral Semaglutide Linked to Fewer Heavy Drinking Days in Small Randomized Trial

Study: GLP‑1 Use Soared and Shifted Costs From Patients to Insurers and Taxpayers

Study Finds Small Increase in Optic‑Nerve Injury With GLP‑1 Diabetes Drugs

Large Penn Study Finds GLP‑1 Use Tied to Lower Breast Cancer Rates

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

Major U.S. Societies Publish First Clinical Guideline for Cardiovascular‑Kidney‑Metabolic Syndrome

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

Study Shows Medically Tailored Meals Cut Hospitalizations 31% and Nearly Pay for Themselves

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

VDR Gene Variant Tied to 19% Lower Diabetes Risk With High-Dose Vitamin D3

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

ACLM Releases ‘Project Remission’ Film Series on Lifestyle Treatment for Type 2 Diabetes

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Kodiak’s Zenkuda Hits Phase 3 Goal in Diabetic Retinopathy Prompting Faster FDA Filing

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

Beta Bionics Beats Q4 Estimates, Sets 2026 Guidance With Pharmacy-Channel Targets

GLP-1 Era Hits the Mainstream With Super Bowl Ads as Costs Rise and Care Shifts to Maintenance